Cellectricon s Q1 Sales Balloon 160 Percent; Firm Lands First Customer for Electroporation Device | GenomeWeb

Swedish biotech tool provider Cellectricon this week said that revenues for the first quarter of 2006 increased 160 percent year over year, driven by sales of its flagship platform for high-throughput microfluidic-based ion channel screening.

The company also said that it has sold a CellAxess system for single-cell electroporation of difficult-to-transfect cells to the Karolinska Institutet in Sweden, marking the first customer for this product since it was launched in December.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.